课题基金 / 基金详情

Identification of an immunohistochemical biomarker panel in resected non-small cell lung cancer (NSCLC) patients that can predict patient outcomes and benefit from adjuvant chemotherapy

Identification of an immunohistochemical biomarker panel in resected non-small cell lung cancer (NSCLC) patients that can predict patient outcomes and benefit from adjuvant chemotherapy
在切除的非小细胞肺癌 (NSCLC) 患者中鉴定免疫组织化学生物标志物组，可以预测患者的结果并从辅助化疗中获益
批准号：
368350
负责人：
Grieve Stacy
金额：
$0.07万
依托单位：
University of New Brunswick (St. John)
依托单位国家：
加拿大
项目类别：
财政年份：
2017
资助国家：
加拿大
项目状态：
已结题
起止时间：
2017-07-01 至 2018-07-01
来源：
https://webapps.cihr-irsc.gc.ca/decisions/p/project_details.html?applId=368350&lang=en
关键词：
Ics Travel Awards

项目摘要

项目成果

Grieve Stacy的其他基金

相关文献

中文摘要
翻译
点击翻译按钮获取中文摘要
英文摘要
Lung cancer accounts for the largest number of cancer-related deaths. Surgery offers the best chance of survival for early-stage lung cancer patients. Several studies have also suggested that post-surgical chemotherapy can improve survival in approximat
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Calpain deregulation potentiates Hsp90 inhibition in orthotopic mouse models of breast cancer
Identifying substrates of the calpain protease system and elucidating the role of calpain in the cancer cell signalling network